Drug Combination Details
| General Information of the Combination (ID: C30515) | |||||
|---|---|---|---|---|---|
| Name | Sulforaphane NP Info | + | PR-104A Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Colorectal cancer
[ICD-11: 2B91]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | AKR1C3 | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | HT29 | CVCL_A8EZ | Colorectal adenocarcinoma | Mus musculus | ||
| SW620 | CVCL_0547 | Colon adenocarcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Sulforaphane preconditioning sensitizes human colon cancer cells towards the bioreductive anticancer prodrug PR-104A. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Sulforaphane Preconditioning Sensitizes Human Colon Cancer Cells towards the Bioreductive Anticancer Prodrug PR-104A. PLoS One. 2016 Mar 7;11(3):e0150219. | |||
